Cell Host & Micro:HIV的毒力依赖于其在宿主DNA的插入位点

2014-11-17 佚名 生物谷

日前,一篇发表在国际杂志Cell Host & Microbe上的研究论文中,来自比利时鲁汶大学(KU Leuven)的研究人员通过研究发现,人类免疫缺陷病毒(HIV)可以在其感染宿主机体DNA的不同位置进行插入,而这种特殊的插入整合位点也决定了患者疾病的进展程度。 当HIV进入到血液中后病毒颗粒会结合并且入侵感染者的免疫细胞,随后HIV会重编程入侵的细胞从而制造新的HIV病毒颗粒;

日前,一篇发表在国际杂志Cell Host & Microbe上的研究论文中,来自比利时鲁汶大学(KU Leuven)的研究人员通过研究发现,人类免疫缺陷病毒(HIV)可以在其感染宿主机体DNA的不同位置进行插入,而这种特殊的插入整合位点也决定了患者疾病的进展程度。

当HIV进入到血液中后病毒颗粒会结合并且入侵感染者的免疫细胞,随后HIV会重编程入侵的细胞从而制造新的HIV病毒颗粒;HIV蛋白整合酶在该过程中扮演着重要角色,其可以识别宿主DNA的短片段从而催化病毒DNA插入到宿主DNA的整个过程。

整合酶可以将病毒DNA插入到人类机体细胞DNA中,但是病毒如何选择插入位点一直是一个谜,这个谜困扰了病毒学家20多年。本文研究中,研究者发现病毒DNA插入到宿主细胞DNA中依赖于两个氨基酸,HIV整合酶由超过200个氨基酸形成的链组成,其可以折叠形成一种特殊结构,通过对这种模型进行模型化,研究者在和宿主DNA直接接触的蛋白质上发现了两个位点,这两个氨基酸位点就决定了HIV的整合位点,这不仅仅是HIV甚至是和动物源性病毒都相关的。

随后研究人员通过对HIV整合位点进行操作,通过改变特殊HIV整合酶氨基酸后,研究者发现,病毒DNA可以在不同位置整合到宿主DNA中,而这也是动物性病毒经常发生的行为;Rik Gijsbers教授表示,我们还发现HIV整合酶可以发生改变,有时候不同的氨基酸会出现在鉴别出的两个位点中,这些突变病毒同样也会在不同的位点整合入宿主的DNA中。

最后研究者表示,当病毒的整合位点发生改变后疾病就会很快发展,换句话说,突变的病毒会更快速地破坏机体的免疫系统,最后研究者希望通过重新将病毒的整合位点靶向至宿主DNA的安全区域,或许就可以帮助开发治疗HIV感染的新疗法。

原始出处

Jonas Demeulemeester, Sofie Vets, Rik Schrijvers, Paradise Madlala, Marc De Maeyer, Jan De Rijck, Thumbi Ndung’u, Zeger Debyser7, Rik Gijsbers7.HIV-1 Integrase Variants Retarget Viral Integration and Are Associated with Disease Progression in a Chronic Infection Cohort.Cell Host & Micro.2014

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959190, encodeId=0b28195919013, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 10 16:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084109, encodeId=8d35208410970, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun May 10 00:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857332, encodeId=5028185e332ee, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Dec 16 10:11:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868944, encodeId=330f18689448c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 25 08:11:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404638, encodeId=e6bf140463897, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Wed Nov 19 00:11:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2015-05-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959190, encodeId=0b28195919013, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 10 16:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084109, encodeId=8d35208410970, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun May 10 00:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857332, encodeId=5028185e332ee, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Dec 16 10:11:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868944, encodeId=330f18689448c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 25 08:11:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404638, encodeId=e6bf140463897, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Wed Nov 19 00:11:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2015-05-10 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959190, encodeId=0b28195919013, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 10 16:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084109, encodeId=8d35208410970, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun May 10 00:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857332, encodeId=5028185e332ee, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Dec 16 10:11:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868944, encodeId=330f18689448c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 25 08:11:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404638, encodeId=e6bf140463897, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Wed Nov 19 00:11:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959190, encodeId=0b28195919013, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 10 16:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084109, encodeId=8d35208410970, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun May 10 00:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857332, encodeId=5028185e332ee, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Dec 16 10:11:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868944, encodeId=330f18689448c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 25 08:11:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404638, encodeId=e6bf140463897, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Wed Nov 19 00:11:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959190, encodeId=0b28195919013, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 10 16:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084109, encodeId=8d35208410970, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun May 10 00:11:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857332, encodeId=5028185e332ee, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Dec 16 10:11:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868944, encodeId=330f18689448c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Oct 25 08:11:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404638, encodeId=e6bf140463897, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Wed Nov 19 00:11:00 CST 2014, time=2014-11-19, status=1, ipAttribution=)]
    2014-11-19 wincls

相关资讯

HIV发现者谈艾滋研究进展

一年一度的林道诺贝尔奖得主大会,对于与会的年轻人来说绝对是足以改变一生的宝贵经历。本期Nature杂志以“Medical Research Masterclass”为题,推出了2014林道诺贝尔奖得主大会专题。该专题记录了多位诺贝尔奖得主与青年学者的直接交流。 法国巴斯德研究所的弗朗索瓦丝·巴尔-西诺西(Françoise Barré-Sinoussi)因为发现H

英国牙科医生因操作不当或致2万名病人感染HIV

据英国《卫报》11月12日报道,英格兰约2.2万名牙科病人因其牙医在感染控制环节处理不当,被敦促报告接受血液传染病HIV、乙肝和丙肝病毒的检测结果。 报道称,英格兰国民医疗服务系统正在尝试追踪那些接受过牙医德斯蒙德(Desmond D’Mello)治疗过的牙科病人。德斯蒙德曾经在诺丁汉郡戴布鲁克一家牙科诊所就职长达32年。 据悉,早在今年6月,此事就被一名告密者

JAIDS:HIV感染者新希望,抗逆转录病毒治疗

近日旧金山加州大学新临床研究显示,与那些不使用兴奋剂的感染艾滋病毒的人相比,341名使用冰毒和可卡因的感染艾滋病毒的人通过抗逆转录病毒的方法治疗初步见效。 “艾滋病患者用抗逆转录病毒疗法常常遇到困难,部分原因由于医疗服务提供者的担忧,他们不能准确把握药物定向。来自本研究的发现表明,许多兴奋剂使用者能够准确把握抗逆转录病毒治疗方法,这样足以避免引起消极的临床后果。抗逆转录病毒疗法能引起一些较好

Genes Dev:美研究发现艾滋病治疗新靶点

HIV就像一条沉睡的巨龙,可以潜伏在一个人的细胞内很多年,规避治疗,在晚些时候才会醒来和发作,快速复制自我并破坏免疫系统。 最近,美国索尔克研究所的科学家们,发现了一种新蛋白,可参与活跃的HIV复制,相关研究结果发表最近的Genes & Development 杂志(2014年最新影响因子12.639)。这个新蛋白,称为Ssu72,是用来将HIV-1

Lancet Infect Dis:病毒性肝炎的筛查对HIV患者至关重要 (2010-2012年 中国免费抗病毒治疗项目)

肝炎相关性肝脏疾病是引起进行联合抗病毒治疗的HIV感染者或免疫缺陷综合征(AIDS)患者发病与死亡的一个主要原因。这一研究主要分析了乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)合并感染对中国HIV感染者预后的影响。我们利用2010-2011年期间中国免费抗病毒治疗项目中的数据进行了一个全国性的回顾性观察性队列研究。对大于18岁,刚开始接受标准抗病毒治疗,而且已经检测出HBV和HCV阳性的病人进行

Nature:欧洲科学家观测到不成熟HIV结构

欧洲分子生物学实验室(EMBL)的科学家以及来自海德堡大学的合作者们,获得了第一个极高分辨率的不成熟HIV结构,并精确地描绘出了每个构件位于病毒中的确切位置。这一发表在11月2日《自然》(Nature)杂志上的研究,揭示出不成熟HIV的构件按照一种惊人的方式进行排列。 该研究工作的领导者、欧洲分子生物学实验室的John Briggs说:“这一结构与我们预期的完全不同。我们猜想,像H